Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye.
It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Dry Eye Disease Keratoconjunctivitis Sicca |
Drug: Lotemax Drug: Restasis |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine |
- Ocular Surface Disease Questionnnaire Results
- Lissamine green staining
- Fluorescein Staining
- Schirmer testing
| Enrollment: | 5 |
| Study Start Date: | November 2006 |
| Study Completion Date: | September 2007 |
| Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
Dry eye is an ocular surface disease that produces discomfort and irritation. Estimated prevalence ranges from 20 million people in the US being affected with mild to moderate dry eye, to as many as one out of every five Americans.
A growing body of evidence has associated ocular inflammation with the signs and symptoms of dry eye.
Restasis is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with a condition called keratoconjunctivitis sicca. The relief of dry eye signs and symptoms with Restasis therapy is often delayed by 1 to 6 months from the initiation of therapy. Stinging on installation, particularly when initiating therapy, has been reported.
Lotemax, an ophthalmic corticosteroid, targets inflammation with a unique, site-active mechanism of action.Structural modifications associated with an ester ophthalmic steroid make Lotemax highly lipid soluble, enhancing penetration into cells and enabling Lotemax to exert anti-inflammatory activity within the eye. Lotemax is indicated for the treatment of steroid responsive inflammatory conditions associated with the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Eligibility| Ages Eligible for Study: | 30 Years to 80 Years (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Between the ages of 30 and 80 inclusive.
- Has not worn contact lenses for at least 1 month prior to the study and agrees to not wear contact lenses during study.
- Oral medications stable 1 month prior to study.
- Oral medications anticipated to be stable during 60 day study.
- Patient is in generally good & stable overall health.
- Patient likely to comply with eye drop regimen, study guidelines & study visits.
- Corneal stain > 1+ or Conjunctival stain > 1+ or OSDI equal or > 5 or using regular artificial tears at least on average twice daily.
- Informed consent signed.
Exclusion Criteria:
- History of Stevens-Johnson Syndrome or Ocular Pemphigoid.
- Punctal plugs inserted or punctal cautery in the past 3 months.
- Intra-ocular surgery within 6 months or ocular laser surgery within 3 months.
- History of liver disease.
- Pregnant or lactating women.
- Severe clinical vitamin deficiencies or history of vitamin overdose.
- Highly variable vitamin intake.
- Unstable use of systemic or topical medications known to create dry eye.
- Corneal pathology, which could, of itself, cause an ocular surface disorder.
- Use of glaucoma medications, topical or oral.
- Unstable diabetes mellitus.
- Allergy or sensitivity to Lotemax, Restasis or the OTC Tear Supplement.
- Use of topical steroids or Restasis within the past 1 month.
- Use of other topical ocular agents other than tear replacements within the past 1 week.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00407043
| United States, New York | |
| Ophthalmic Consultants of Long Island | |
| Lynbrook, New York, United States, 11563 | |
| Study Director: | Maria Howard | Ophthalmic Consultants of Long Island |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr. Eric Donnenfeld, OCLI |
| ClinicalTrials.gov Identifier: | NCT00407043 History of Changes |
| Other Study ID Numbers: | Donnenfeld Review 1 |
| Study First Received: | November 30, 2006 |
| Last Updated: | July 20, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Ophthalmic Consultants of Long Island:
|
Dry Eye Disease Lotemax Restasis Loteprednol Cyclosporine |
Additional relevant MeSH terms:
|
Keratoconjunctivitis Sicca Dry Eye Syndromes Eye Diseases Keratoconjunctivitis Conjunctivitis Conjunctival Diseases Keratitis Corneal Diseases Lacrimal Apparatus Diseases Cyclosporins Cyclosporine Loteprednol Etabonate |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Anti-Allergic Agents |
ClinicalTrials.gov processed this record on September 23, 2016